BerGenBio ASA (OSL:BGBIO)

Market Cap	46.04M
Revenue (ttm)	5.41M
Net Income (ttm)	-107.58M
Shares Out	39.09M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,735
Average Volume	64,885
Open	1.132
Previous Close	1.178
Day's Range	1.132 - 1.160
52-Week Range	1.020 - 15.670
Beta	1.20
RSI	43.92
Earnings Date	Aug 20, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Oslo Børs
• Ticker Symbol: BGBIO

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.